OR7G1

Across TCGA pan-cancer cohorts, OR7G1 Mutation is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated OR7G1 data layer compared with 7 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher OR7G1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR7G1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

DLBC, LUAD, and LIHC are the cancer types where OR7G1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	15	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
UCEC	DFS	Median	III,IV	1.000	0.540	.037	8	view →
SARC	DFS	Median	All	0.101	0.632	.011	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	III,IV	0.742	0.483	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

OR7G1–DLBC (DFS)

Open the DLBC breakdown →